Trial Profile
A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 May 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms AGO-OVAR9
- 21 Sep 2020 Results assess the role of KELIM regarding the probability of long progression-free survivorship (PS) > 5 years after 1st line treatment (AGO-OVAR 9; AGO-OVAR 7 and ICON 7) presented at the 45th European Society for Medical Oncology Congress
- 01 Apr 2019 Results validating the higher predictive & prognostic values of KELIM during first line treatments in ovarian cancer patients published in the Clinical Cancer Research
- 06 Jun 2017 Results (n=4578) of validation of prognostic value of KELIM regarding PFS and OS in phase 3 trial (AGO-OVAR 9, AGO-OVAR 7, ICON 7) datasets presented at the 53rd Annual Meeting of the American Society of Clinical Oncology